AbbVie Inc. and Bristol-Myers Squibb Company said Monday morning they will collaborate on a clinical trial for a lung cancer treatment combining AbbVie's Rova-T with Bristol-Myers Squibb's Opdivo and an Opdivo + Yervoy regimen. The phase 1/2 trial will evaluate the combination's effectiveness for relapsed extensive-stage small cell lung cancer. Lung cancer is the top cause of U.S. cancer deaths. AbbVie shares rose 4.7% over the last three months, and Bristol-Myers Squibb shares rose 7.2%, compared with a 4.2% rise in the S&P 500 .
Copyright © 2016 MarketWatch, Inc.
Continue Reading Below